HOME > TOP STORIES
TOP STORIES
-
REGULATORY Ministers Agree on 5%-Plus Price Discrepancy Line for Off-Year Re-Pricing; 59% Coverage for Innovative Meds, 88% for LLPs, 83% for Gx
December 18, 2020
-
REGULATORY Govt Settles on Discrepancy Rate Threshold of “Above 5%” for Off-Year Drug Re-Pricing, 430 Billion Yen Reduction, 60% Coverage for Innovative Meds
December 17, 2020
-
REGULATORY Japan Govt Eyes 4-6% Price Discrepancy Threshold for Off-Year Drug Re-Pricing
December 16, 2020
-
BUSINESS UCB Japan to Independently Market New Products; Stand-Alone E Keppra Sales “Going Smoothly”: President
December 16, 2020
-
REGULATORY Japan Weighs Drug Cost Cut of around 400 Billion Yen in Off-Year Re-Pricing, Expanded Coverage Including Products with Smaller-than-Average Price Gap Too
December 15, 2020
-
BUSINESS Forxiga Filed for Chronic Kidney Disease in Japan: AZ
December 15, 2020
-
BUSINESS 1st Death Reported for Kobayashi Kako’s Tainted Itraconazole Product
December 14, 2020
-
REGULATORY MHLW Unveils Overview of COVID-19 Vaccine Distribution Scheme in Japan
December 11, 2020
-
BUSINESS Boehringer Speeding Up Growth of Jardiance on Organization, Alliance Rejig; 40 Billion Yen Japan Sales Likely in 2020
December 11, 2020
-
BUSINESS Aducanumab Submitted in Japan, but Decision Unlikely to Come Until Next Autumn
December 11, 2020
-
BUSINESS Biogen Files Japan NDA for Aducanumab
December 10, 2020
-
REGULATORY Chuikyo Healthcare Reps Urge Minimal Scope for Off-Year Re-Pricing, Payers Grumble over Generic-Heavy Coverage
December 10, 2020
-
BUSINESS Takeda Aiming for Sales of 5 Trillion Yen by FY2030, Sees It Realistic Target with Strong Pipeline
December 10, 2020
-
REGULATORY MHLW Estimates: Off-Year Re-Pricing with Average Price Gap Threshold Likely to Hit 8,700 Products, Save 360 Billion Yen
December 9, 2020
-
BUSINESS Kyle Tattle to Take Reins of MSD Japan from January
December 8, 2020
-
REGULATORY MHLW Panel OKs Takeda’s ALK Drug, Lynparza’s Pancreatic Cancer Use; Seikagaku’s Osteoarthritis Med Put under Continued Review
December 7, 2020
-
REGULATORY Gardasil’s Male Indication in Line for OK as Early as This Month
December 7, 2020
-
BUSINESS Kobayashi Kako Recalls Itraconazole over Hypnotic Contamination; Side Effects Confirmed
December 7, 2020
-
REGULATORY Yescarta Sails through PAFSC Review; Panel Roughly OKs Novartis’ Corrective Measures after Zolgensma Delay
December 4, 2020
-
BUSINESS Sandoz to Discontinue Filgrastim Biosimilars; Late Market Entry a Factor
December 4, 2020
ページ
On paper, things should be looking up for Japan’s pharmaceutical wholesalers. Industry expectations are mounting that the average gap between NHI and market prices will narrow further in FY2026 from the previous year’s record low of 4.8%.A shrinking gap should…
Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…
